Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Smith & Nephew PLC ORD USD0.20 (SN.)

Related News

30-Nov-2016 07:31 AM

Smith & Nephew appoints Graham Baker as CFO

Smith & Nephew announces the appointment of Graham Baker as Chief Financial Officer. He will formally begin the role on 1 March 2017 when he will also be appointed to the Board as an Executive Director. Story provided by
06-Oct-2016 08:30 AM

Broker Forecast - Berenberg issues a broker note on Smith & Nephew PLC

Berenberg today downgrades its investment rating on Smith & Nephew PLC (LON:SN.) to hold (from buy) and cut its price target to 1340p (from 1485p). Story provided by
29-Jul-2016 01:00 PM

Broker Forecast - JP Morgan Cazenove issues a broker note on Smith & Nephew PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on Smith & Nephew PLC (LON:SN.) and raised its price target to 1199p (from 1196p). Story provided by
28-Jul-2016 07:26 AM

SN.'s profit slips

Smith & Nephew's H1 pretax profit has slipped to $327m, from $411m a year earlier, with revenue higher at $2.33bn, from $2.27bn. Interim dividend was 12.3 cents a share, from 11.8 cents. CEO Olivier Bohuon said Q2 saw the continuation of many of th
01-Jul-2016 04:10 PM

Broker Forecast - JP Morgan Cazenove issues a broker note on Smith & Nephew PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on Smith & Nephew PLC (LON:SN.) and raised its price target to 1196p (from 1096p). Story provided by
30-Jun-2016 08:10 AM

Broker Forecast - Jefferies International issues a broker note on Smith & Nephew PLC

Jefferies International today reaffirms its buy investment rating on Smith & Nephew PLC (LON:SN.) and raised its price target to 1420p (from 1375p). Story provided by
09-May-2016 08:40 AM

Broker Forecast - Jefferies International issues a broker note on Smith & Nephew PLC

Jefferies International today upgrades its investment rating on Smith & Nephew PLC (LON:SN.) to buy (from hold) and raised its price target to 1375p (from 1044p). Story provided by
08-Feb-2016 08:20 AM

Broker Forecast - JP Morgan Cazenove issues a broker note on Smith & Nephew PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on Smith & Nephew PLC (LON:SN.) and cut its price target to 1072p (from 1089p). Story provided by
24-Sep-2015 04:18 PM

SN cancels treasury shares

Smith & Nephew has announced that it has today cancelled 505,000 of its Ordinary Shares of US 20�¢ each previously held in Treasury. The Company said that these shares were issued in connection with employee share schemes in Quarter 2 2015 and have
30-Jul-2015 07:38 AM

Smith & Nephew lifts H1 pretax profit

Smith & Nephew has lifted its H1 pretax profit to $411m, from $349m. Revenue was $2.27bn, from $2.22bn. Interim dividend was 11.8 cents a share, from 11.0 cents. CEO Olivier Bohuon said: "These strong results demonstrate the positive effects of our
30-Jul-2015 07:23 AM

Smith & Nephew lifts H1 pretax profit

Story provided by
10-Jul-2015 07:18 AM

S&N's deal

Smith & Nephew has acquired the trauma and orthopaedics business of DeOst LLC and DC LLC, a manufacturing company in the DeOst group. DeOst has distributed Smith & Nephew's products in Russia since 2009. "The acquisition brings us closer to our
30-Apr-2015 07:50 AM

Smith & Nephew says Q1 revenue up 3%

Smith & Nephew has booked Q1 revenue of $1,104 million, up 3% on an underlying basis. Reported growth of 3% includes effects of -8% currency headwind offset by 8% benefit from acquisitions. The company's full-year outlook remains unchanged, it said.
15-Apr-2015 02:27 PM

Smith & Nephew schedules Q1 report

Smith & Nephew, the global medical technology business, will announce its trading report for the first quarter on 30 April. At 2:27pm: (LON:SN.) Smith Nephew PLC share price was -4.5p at 1175.5p Story provided by
03-Mar-2015 02:06 PM

Smith & Nephew acquires Colombian distributor ECC

Smith & Nephew, the global medical technology business, has acquired EuroCiencia Colombia. ECC has been Smith & Nephew's sole distributor for orthopaedic reconstruction, trauma and sports medicine products in Colombia since 2006. Chief executive O
05-Feb-2015 07:22 AM

SN. profit slips

Smith & Nephew's FY pretax profit came in at $714m, from $802m a year earlier. Revenue was $4.6bn, from $4.4bn. It proposed a final dividend of 18.6 cents, taking the total up 8% to 29.6 cents. CEO Olivier Bohuon said the 2014 performance reflects t
13-Nov-2014 11:24 AM

Chief executive of Reed Elsevier joins Board of Smith & Nephew

Smith & Nephew, the global medical technology business, has announced that Erik Engstrom, who has been chief executive of Reed Elsevier since 2009, is to join its Board. He will become a non-executive director at the start of next year. At 11:24am
30-Oct-2014 12:27 PM

New director at Smith & Nephew

Smith & Nephew, the global medical technology business, has announced that Vinita Bali is to join its Board as a non-executive director. on 1 December 2014. Ms Bali was most recently managing director and chief executive officer of Britannia Industries,
13-Oct-2014 03:57 PM

Smith & Nephew schedules Q3 results

Smith & Nephew, the global medical technology business, will announce its third quarter results to 27 September on 30 October. At 3:57pm: (LON:SN.) Smith Nephew PLC share price was -16.5p at 974.5p Story provided by
01-Aug-2014 08:29 AM

Smith & Nephew H1 pretax profit marginally lower

Smith & Nephew booked an H1 pretax profit of $349m, from $392m. Revenue totalled $2,220m, from $2,149m. In the second quarter, pretax profit was $188m, from $128m. CEO Olivier Bohuon said Sith & Nephew had delivered a good increase in revenues and tradin
11-Jul-2014 01:37 PM

Smith & Nephew ends 77-year link with external auditor

Smith & Nephew is set to change its external auditor for the first time since the company listed in 1937. Shareholders will be asked to approve KPMG as auditor for the year to 31 December 2015 - ending the company's 77-year link with Ernst & Young.
10-Jul-2014 01:01 PM

Smith & Nephew schedules interims

Smith & Nephew, the global medical technology business, will announce its results for the second quarter and half year ended 28 June on 1 August. At 1:01pm: (LON:SN.) Smith Nephew PLC share price was -5.5p at 1017.5p Story provided by StockMarketWi
29-May-2014 03:25 PM

Smith & Nephew completes ArthroCare acquisition

Smith & Nephew has completed the acquisition of ArthroCare Corporation, an innovative medical device company with a highly complementary sports medicine portfolio. The purchase price was $48.25 per share paid in cash, translating into an enterprise valu
28-May-2014 02:48 PM

Stryker does not intend to make offer for Smith & Nephew

Stryker Corporation has confirmed it does not intend to make an offer for Smith & Nephew. Stryker said it noted speculation regarding a potential transaction and recent movement in the share price of Smith & Nephew. Stryker said that at the request
01-May-2014 08:28 AM

Smith & Nephew Q1 underlying revenue up 1%

Smith & Nephew said its Q1 underlying revenue was up 1% to $1073m, from a reported $1075m. Trading profit was $229m, down 5% in underlying terms from $241m. There was a -1% currency headwind and a net zero effect from acquisitions and disposals. CEO Ol
Top categories
Company finder

a d v e r t i s e m e n t